On Saturday, the FDA approved GSK plc’s (NYSE:GSK) Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25. 

The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which commonly cause invasive meningococcal disease (IMD).

The vaccine combines the antigenic components of GSK’s two well-established meningococcal vaccines, Bexsero (Meningococcal Group B Vaccine) and Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine).

Also Read: GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion

The regulatory application was supported by results from two phase 3 trials, which evaluated the vaccine’s safety, tolerability, and immune response in over 4,800 participants aged 10-25. 

The safety data demonstrated that the vaccine has a safety profile consistent with GSK’s licensed meningococcal vaccines.

Integrating GSK’s MenABCWY vaccine into healthcare provider practices could simplify meningococcal vaccination delivery and help protect more U.S. adolescents against the five common disease-causing serogroups—A, B, C, W, and Y—for which the US Centers for Disease Control and Prevention (CDC) have issued recommendations.

Although MenB is the leading cause of IMD among this population, less than 13% receive the recommended two-dose vaccination series; around 32% receive at least one dose. GSK manufactures three of every four MenB doses currently administered in the U.S., positioning the company well to lead in the U.S. market as MenB-containing vaccinations must be completed with the same manufacturer’s MenB vaccine.

At its meeting on February 26, 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) is expected to vote on recommendations for the appropriate use of GSK’s MenABCWY vaccine in adolescents and young adults.

Price Action: GSK stock is up 0.64% at $36.41 during the premarket session on last check Tuesday.

Read Next:

• Roku’s Growth Surges: Analysts Raise Price Targets As Company Expands Ad Reach

Photo by HJBC via Shutterstock

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

• GSK (GSK): Free Stock Analysis Report

This article FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.